We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures ... Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst others.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

president of Lilly Oncology. The agreement includes an upfront payment and subsequent payments upon achieving certain regulatory and sales milestones. As part of the deal, Scorpion will spin out a ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

BeyondSpring (BYSI) has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics for gross ...

Beyond Mounjaro and Zepbound, I'd encourage investors to take a serious look at Lilly's oncology business. Below, I'll explore how the company is quietly making significant strides in treating ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...